对比剂致急性肾损伤研究进展  

Research progress in contrast-induced acute kidney injury

作　　者：李鸿杰[1] 唐方明[2] 

机构地区：[1]广东医学院研究生院,广东湛江524000 [2]广东省农垦中心医院心血管内科,广东湛江524000

出　　处：《心脏杂志》2015年第2期241-245,共5页Chinese Heart Journal

摘　　要：随着冠状动脉介入治疗的快速发展,对比剂的使用越来越广泛,但随之出现的对比剂致急性肾损伤(CI-AKI)目前已成为医院内获得性急性肾衰竭的第3位原因,并且发病率和病死率逐年增加。虽然临床研究者对CI-AKI的发病机制及危险因素研究日趋加深,但由于目前仍缺乏切实有效的防治策略,CI-AKI仍然是重要的临床问题。本文将就CI-AKI的诊断标准、发病机制、危险因素、预防策略及近期研究进展做一综述。With the rapid development of coronary artery interventional therapy,contrast media is used more and more widely,but contrast-induced acute kidney injury（ CI-AKI） ranks as the third reason for hospital-acquired acute renal failure with a yearly increase in the incidence and mortality rate. Although more studies have been conducted on the pathogenesis and clinical risk of acute renal injury induced by the contrast factors,CI-AKI is still an important clinical problem due to lack of an effective strategy for the prevention of CI-AKI. This article will focus on the recent research progress in the diagnosis,pathogenesis,risk factors,and prevention strategies of CI-AKI.

关 键 词：对比剂 急性肾损伤 冠状动脉介入治疗 水化 

分 类 号：R699.2[医药卫生—泌尿科学]